DUBLIN – The global market for unproven cell therapies may be worth as much as $2.4 billion, according to a report published Thursday by the International Society for Cellular Therapy (ISCT).
DUBLIN – Minoryx Therapeutics SL closed a €19.4 million (US$22.1 million) series A round to take forward a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist in X-linked adrenoleukodystrophy (ALD).
DUBLIN – Glycosylation specialist Glycotope GmbH is getting €80 million (US$90 million) up front as part of a licensing and equity investment deal with Octapharma AG covering a preclinical portfolio of blood coagulation factors.
DUBLIN – Proteros Biostructures GmbH could bank up to $126 million in up-front and research funding, as well as milestone payments, from a drug discovery deal with Merck & Co. focused on an undisclosed epigenetic cancer target. The deal also involves tiered royalties on product sales.
DUBLIN – French start-up Therachon SAS raised $35 million in a series A round to take forward a new treatment for achondroplasia, an autosomal dominant bone growth disorder that causes short-limbed dwarfism.
DUBLIN – Advanced Accelerator Applications SA (AAA) surpassed even its own expectations in a phase III trial of its lead therapy Lutathera (177-Lu-Dotatate), which was pitted against a double dose of Sandostatin LAR in patients with somatostatin receptor positive midgut neuro endocrine tumors (midgut NETs)
DUBLIN – The pioneering team behind Amgen Inc.'s oncolytic viral therapy talimogene laherparepvec (T-vec) has re-surfaced in a new venture, Replimune Ltd., which closed a $30 million series A round to take forward a new generation of the technology.
DUBLIN – Shares in AB Science SA dipped just 4.7 percent Tuesday on news that it was halting a phase III trial of its tyrosine kinase inhibitor (TKI), masitinib, in rheumatoid arthritis (RA) following a futility analysis, which showed the study's probability of success was below 50 percent.
DUBLIN – Oryzon Genomics SA, one of Spain's flagship biotech firms, is seeking to give the country's sector greater national and international visibility by listing its shares on the main market of the Madrid Stock Exchange (Bolsa de Madrid) in the coming weeks, after which it plans to seek a listing on Nasdaq.
